"Pharmaceutical headline jun" ShuMeile ten years price increase 18 times! AbbVie was summoned for high pricing

(2020/09/03) Health care account reform controversy: said it let personal income shrink is not a misreading; PD-1 first-tier revenue ranking big open innovative pharmaceutical companies commercialization ability in the end; Sorafeini first imitation net price of 3990 yuan / box for 70% of the original research price ... (Click on the title to get the original text) "Pharmaceutical 1st Time" ten-year price increase 18 times! AbbVie was summoned by the U.S. House Oversight and Reform Committee (U.S.) for high pricing by "Drug King" Shumeile. House Oversight and Reform Committee is conducting a drug pricing investigation, including AbbVie's drug for rheumatoid arthritis and other inflammatory diseases, which generated nearly $20 billion in revenue for AbbVie in 2019.
U.S. government noted that in the 10 years from 2009 to 2019, AbbVie raised the price of the ride 18 times.
: Shumeile has been the world's best-selling drug as the "King of Drugs."
health care reform controversy: Is it a misreading to say it's shrinking personal income? The point of contentious conflict may be: is the money in a personal account essentially insurance or saving? If you can't use it now, should it be left to the sick or old in the future, or should you help those who need it now, and get help from others when you need it in the future? Headline: Whose money is in a personal account? E drug manager: PD-1 first echelon revenue ranking is very public! What is the commercialization capability of innovative pharmaceutical companies? At present, 8 PD-1/L1-owned enterprises have announced the first half of 2020 results, PD-1/L1 first-tier results are generally rising rapidly, the market size gradually opened up, but the differentiation is also increasingly apparent, health care and sales capacity has become the key.
headlines: The 2020 health-care catalog is a must-have for these drug companies.
The booming large ring small molecule drug large ring small molecule drug is a hot spot in the field of pharmaceutical chemistry in the past 20 years, because the large ring structure in improving pharmacological activity and selectivity, perfecting the pharmaceutical effect is significant, and takes into account the microstructure combined with the target and the macro-nature of the needs of pharmacodynamics.
large ring small molecule drugs in the clinic are mostly composed of 12 to 20 atoms of cyclopeptides or endoesters, mainly used to treat infections, inflammation and tumors and other diseases, oral and injection forms.
: There has been no successful pin-curing peptide on the market so far.
"Insight Database" Solaphini first imitation hanging net price of 3990 yuan / box for the original research price of 70% of the 1st, Inner Mongolia Autonomous Region drug procurement network issued a notice, Jiangxi Shanxiang Pharmaceuticals toluene sulfonate soralfinid tablets (specifications: 0.2g x 60 tablets) to give supplementary hanging net, purchase price of 3990.00 yuan / box, September 5, 2020 official implementation.
: Sorafeini's sales growth has been significant since it was included in Medicare in 2017.
's tough! To survive, the cell therapy company sold its CAR-T business on August 31st, according to foreign media reports, and the cell therapy-listed company (UMRX) announced that it would sell its BOXR platform and its main candidate CAR-T product, BOXR1030, to SOTO, a Czech biotech company.
agreement, the deal is worth $11.5 million, including an $8.1 million advance payment from SOTO to Unum and a potentially high milestone payment of $3.4 million in the future.
headlines: Buyers rejoice in sellers.
"Village Diary" Traditional health insurance into the core of the U.S. insurance market in the field of commercial health insurance, the United States is a business group procurement-based group insurance market, before the outbreak, the number of U.S. employers paid for group insurance 163 million, 13 million members, 29 million unsecured.
, U.S. government health insurance is second only to commercial coverage, with 60 million Medicare and 71 million Medicaid.
: The largest amount of government health care business is currently the main battleground for large commercial insurance companies.